TRIB (Trinity Biotech) DeferredTaxAndRevenue: $0.19 Mil (As of Dec. 2025)


TRIB Trinity Biotech PLC TRIB
26 GF Score
Price $0.39
GF Value $0.74
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Trinity Biotech DeferredTaxAndRevenue?

Trinity Biotech TRIB -3.97% 26 DeferredTaxAndRevenue is $0.19 Mil as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 26/100 and a GF Value™ of $0.74 (Possible Value Trap). The stock has 6 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Trinity Biotech's current deferred tax and revenue for the quarter that ended in Dec. 2025 was $0.19 Mil.

Trinity Biotech DeferredTaxAndRevenue Related Terms

Trinity Biotech DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Trinity Biotech's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech DeferredTaxAndRevenue Chart

Trinity Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.11 0.05 0.20 0.19

Trinity Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.00 0.20 0.00 0.19
TRIB
26GF Score
Trinity Biotech PLC TRIB
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.19 Mil mean?
Trinity Biotech (TRIB) has a DeferredTaxAndRevenue of $0.19 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Trinity Biotech.
Is Trinity Biotech's DeferredTaxAndRevenue too high?
Trinity Biotech's current DeferredTaxAndRevenue is $0.19 Mil. Overall, Trinity Biotech has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's DeferredTaxAndRevenue compare to AIDX and NVNO?
Trinity Biotech's DeferredTaxAndRevenue of $0.19 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Medical Devices & Instruments company?
A good DeferredTaxAndRevenue depends on the Medical Devices & Instruments industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Trinity Biotech. Trinity Biotech's current DeferredTaxAndRevenue is $0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.74, compared to a current price of $0.39 — trading 47.3% below its estimated fair value. The current DeferredTaxAndRevenue is $0.19 Mil. Trinity Biotech's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current DeferredTaxAndRevenue is $0.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $0.39 is trading 47.3% below its estimated GF Value™ of $0.74. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

  • DeferredTaxAndRevenue: $0.19 Mil
  • GF Value™: $0.74 vs. price of $0.39 (47.3% below fair value)
  • GF Score™: 26/100 with 6 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Trinity Biotech Business Description

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
26GF Score

Get the complete analysis for TRIB

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price
$0.74
GF Value